TL;DR
PCDHGB4 is a potential biomarker for pan-cancer, especially SCC, and may promote tumor progression through oncogenic signaling and modulation of the tumor immune microenvironment.
HIST1H4L was significantly upregulated in SCLC tumors versus normal tissues and enriched in DNA transcription-related pathways and correlated with poor patient survival; critically, high HIST1H4L expression correlated with poor patient survival.
Functional and rescue experiments support MAPK/ERK signaling as a partial mediator of PAXX-associated malignant phenotypes and EMT-related alterations in CRC progression and its association with the tumor immune microenvironment.
ISG20L2 is aberrantly upregulated and associated with malignant biological features and immune-related characteristics in gastric cancer, supporting its potential role as a pro-oncogenic regulator and a candidate molecular indicator requiring further clinical validation.
FKBP10 serves as a reliable prognostic biomarker and a promising therapeutic target for high-risk neuroblastoma and promotes aggressive NB progression by regulating stromal activation, ECM remodeling and malignant behaviors.
PPAP2C exhibits the most significant overexpression pattern across 33 cancer types and was significantly associated with advanced clinical stages and aggressive subtypes (HER2+ and TNBC).
Pan-cancer analysis showed that RBM39 is aberrantly expressed in multiple cancers and is significantly associated with patient prognosis, suggesting its diagnostic value, and RBM39 may serve as a potential diagnostic and therapeutic target for HNSC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
